Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Gross Margin (2016 - 2025)

Historic Gross Margin for Aytu Biopharma (AYTU) over the last 12 years, with Q4 2025 value amounting to 63.46%.

  • Aytu Biopharma's Gross Margin fell 30300.0% to 63.46% in Q4 2025 from the same period last year, while for Dec 2025 it was 66.84%, marking a year-over-year decrease of 51000.0%. This contributed to the annual value of 69.04% for FY2025, which is 62100.0% down from last year.
  • Per Aytu Biopharma's latest filing, its Gross Margin stood at 63.46% for Q4 2025, which was down 30300.0% from 66.14% recorded in Q3 2025.
  • Over the past 5 years, Aytu Biopharma's Gross Margin peaked at 77.89% during Q4 2023, and registered a low of 3.35% during Q1 2021.
  • Moreover, its 5-year median value for Gross Margin was 65.5% (2022), whereas its average is 60.75%.
  • Per our database at Business Quant, Aytu Biopharma's Gross Margin crashed by -788500bps in 2021 and then skyrocketed by 557800bps in 2022.
  • Over the past 5 years, Aytu Biopharma's Gross Margin (Quarter) stood at 53.18% in 2021, then rose by 24bps to 65.81% in 2022, then grew by 18bps to 77.89% in 2023, then dropped by -15bps to 66.49% in 2024, then fell by -5bps to 63.46% in 2025.
  • Its last three reported values are 63.46% in Q4 2025, 66.14% for Q3 2025, and 67.75% during Q2 2025.